Regenicin, Inc.
OTC: RGIN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Randall E. McCoy
- Employees
- 3
- Headquarters
- Little Falls, United States
- IPO year
- 2009
- Market cap
- $15.3K
- Website
- https://www.regenicin.com
Loading RGIN…
Loading profile data…Frequently asked questions about RGIN
What does Regenicin, Inc. (RGIN) do?
Regenicin, Inc. is dedicated to the development and commercialization of advanced tissue-engineered skin replacement technologies. Its product line features NovaDerm, a sophisticated multi-layered living and cultured skin substitute engineered for treating burn injuries, alongside TempaDerm, which addresses more localized wound areas like ulcers...
Where does RGIN trade?
Regenicin, Inc. (RGIN) trades on the Other OTC.
What sector is RGIN in?
Regenicin, Inc. (RGIN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Regenicin, Inc.?
Randall E. McCoy is the chief executive officer of Regenicin, Inc. (RGIN).
Where is Regenicin, Inc. headquartered?
Regenicin, Inc. is headquartered in United States.
Does RGIN pay a dividend?
Regenicin, Inc. (RGIN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RGIN go public?
Regenicin, Inc. (RGIN) completed its initial public offering in 2009.